{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:45:31Z","timestamp":1794329131334,"version":"4.9.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Myositis-specific autoantibodies, such as anti-melanoma differentiation associated gene 5 (MDA5) and anti-anti-amino acyl-tRNA synthetases (ARS) antibodies, are associated with interstitial lung diseases (ILD), which determine the prognosis of polymyositis\/dermatomyositis (PM\/DM) patients. However, there is a paucity of data on the clinical correlation between anti-Sj\u00f6gren syndrome-related antigen A (anti-SSA)\/Ro52 antibodies in PM\/DM. We investigated the prevalence of myositis-specific autoantibodies including anti-SSA\/Ro52 antibody and assessed the clinical significance of these antibodies in patients with PM\/DM.<\/jats:p>\n            <jats:p>We retrospectively reviewed demographic data and clinical outcomes in patients with PM\/DM. The study population comprised 24 patients with PM and 60 patients with DM. The presence of anti-myositis-specific antibodies (MDA5, ARS, Jo-1, SSA\/Ro52) was determined by immunosorbent assay (ELISA).<\/jats:p>\n            <jats:p>Anti-MDA5 antibody was detected in 18 patients with DM (n\u200a=\u200a60). Anti-ARS\/anti-SSA\/Ro52 antibodies were detected in 31 and 39 patients with PM\/DM (n\u200a=\u200a84). Rapidly progressive ILD patients were mainly found in the anti-MDA5 antibody-positive DM group. During the follow-up period, 9 patients died. Kaplan\u2013Meier analysis demonstrated that survival rates seem to be lower in DM patients with anti-MDA5 antibodies compared with those without anti-MDA5 antibodies. Furthermore, dual positivity for anti-SSA\/Ro52 and anti-MDA5 antibodies was significantly higher in nonsurviving DM patients compared with survivors.<\/jats:p>\n            <jats:p>Although the presence of anti-ARS or anti-MDA5 antibodies is a prognostic marker in patients with PM\/DM, combined presence of anti-SSA\/Ro52 and anti-MDA5 antibodies represent another marker for clinical outcome in DM patients. Our results suggest that anti-SSA\/Ro52 antibody positivity in DM patients with anti-MDA5 antibody reveals a subgroup of DM patients with poor prognosis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000015578","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T10:44:01Z","timestamp":1558003441000},"page":"e15578","source":"Crossref","is-referenced-by-count":51,"title":["Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis\/dermatomyositis"],"prefix":"10.1097","volume":"98","author":[{"given":"Jumpei","family":"Temmoku","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ohta Nishinouchi General Hospital Foundation, Nishinouchi, Koriyama, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanno","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Ohta Nishinouchi General Hospital Foundation, Nishinouchi, Koriyama, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko Yashiro","family":"Furuya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Sakamoto, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Hikarigaoka, Fukushima"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12016-015-8517-4","article-title":"The clinical and histological spectrum of idiopathic inflammatory myopathies","volume":"52","author":"Cavazzana","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00002281-200011000-00005","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"12","author":"Hirakata","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","article-title":"A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sin\u00e9 myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies","volume":"54","author":"Gerami","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-alpha is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/00002281-200311000-00005","article-title":"Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies","volume":"15","author":"Levine","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"e0120313","DOI":"10.1371\/journal.pone.0120313","article-title":"Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: a retrospective case control study","volume":"10","author":"Hozumi","year":"2015","journal-title":"PLoS One"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"e85062","DOI":"10.1371\/journal.pone.0085062","article-title":"The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia","volume":"9","author":"Nakashima","year":"2014","journal-title":"PLoS One"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.rmed.2017.04.007","article-title":"The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies","volume":"127","author":"Tanizawa","year":"2017","journal-title":"Respir Med"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00296-017-3729-y","article-title":"Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody","volume":"37","author":"Isoda","year":"2017","journal-title":"Rheumatol Int"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.autrev.2010.09.005","article-title":"Clinical and laboratory aspects of Ro\/SSA-52 autoantibodies","volume":"10","author":"Defendenti","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/rheumatology\/ker267","article-title":"Idiopathic interstitial lung disease with anti-SSA antibody","volume":"50","author":"Boitiaux","year":"2011","journal-title":"Rheumatology"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.autrev.2009.02.010","article-title":"Latest update on the Ro\/SS-A autoantibody system","volume":"8","author":"Schulte-Pelkum","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.autrev.2011.03.004","article-title":"Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study","volume":"10","author":"Ghillani","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/14397595.2015.1091155","article-title":"Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52","volume":"26","author":"Yamasaki","year":"2016","journal-title":"Mod Rheumatol"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/14397595.2017.1317377","article-title":"Anti-SS-A\/Ro antibody positivity as a risk factor for relapse in patients with polymyositis\/dermatomyositis","volume":"28","author":"Tatebe","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/eji.201747381","article-title":"Autoantibodies reactive to PEP08 are clinically related with morbidity and severity of interstitial lung disease in connective tissue diseases","volume":"48","author":"Okumura","year":"2018","journal-title":"Eur J Immunol"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2018.05.010","article-title":"Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies","volume":"140","author":"Yamaguchi","year":"2018","journal-title":"Respir Med"},{"key":"R28-20230914","article-title":"Clinical features of thirty-two patients with anti-melanoma differentiation-associated gene 5 antibodies","author":"Huang","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League against rheumatism classification criteria for primary Sj\u00f6gren syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201905170-00031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T22:19:17Z","timestamp":1694729957000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201905170-00031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":29,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000015578","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}